Compare FTCI & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | PYXS |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 124.2M |
| IPO Year | 2021 | 2021 |
| Metric | FTCI | PYXS |
|---|---|---|
| Price | $4.59 | $1.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $10.80 | $7.00 |
| AVG Volume (30 Days) | 111.9K | ★ 548.9K |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | $13,858,000.00 |
| Revenue This Year | $65.44 | N/A |
| Revenue Next Year | $45.97 | $7,043.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 110.51 | N/A |
| 52 Week Low | $3.21 | $0.97 |
| 52 Week High | $12.75 | $5.55 |
| Indicator | FTCI | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 44.07 |
| Support Level | $4.15 | $1.60 |
| Resistance Level | $5.31 | $1.74 |
| Average True Range (ATR) | 0.49 | 0.19 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 20.43 | 27.65 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.